Recombinant Human Complement C

Recombinant Human Complement Component C3a/C3a  (CP21)

产品说明(Description)

Recombinant Human Complement Component C3a  is produced by our E.coli expression system and the target gene encoding Ser672-Arg748 is expressed. 

Accession #: P01024

Known as: Complement Component C3a; C3a; Anaphylatoxin

 

制剂(Formulation)

Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH7.4.

 

质量控制(Quality Control) 

 

Purity:        Greater than 95% as determined by reducing SDS-PAGE.    

Endotoxin: Less than 0.1 ng/ug (1 EU/ug) as determined by LAL test.

 

复溶(Reconstitution)

Always centrifuge tubes before opening. Do not mix by vortex or pipetting.
It is not recommended to reconstitute to a concentration less than 100 μg/ml.
Dissolve the lyophilized protein in distilled water.
Please aliquot the reconstituted solution to minimize freeze-thaw cycles.    

 

保存(Storage)

Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks.Reconstituted protein solution can be stored at 4-7°C for 2-7 days.Aliquots of reconstituted samples are stable at < -20°C for 3 months.     

 

背景(Background)

Complement is defined as key part of innate immunity and as the first line of defense in the fight against invading pathogens. Complement 3 (C3) is the most abundant component of the complement cascade and the convergent point for all three major complement activation pathways: namely classical, alternative and mannose-binding lectin pathways. Complement activation leads to the formation of the C3 convertase, which cleaves C3 into the key effector molecules, C3a (anaphylatoxin) and C3b (opsonin) which then drive microbe removal. By binding to C3a receptor (C3aR), C3a exhibits potent anaphylatoxin activity, including increased vascular permeability, triggering degranulation of mast cells, inflammation, and activating leukocytes.

 

电泳(SDS-PAGE)

 

参考文献(Reference)

Trajectory modeling of endothelial-to-mesenchymal transition reveals galectin-3 as a mediator in pulmonary fibrosis[J]. Wangyue Jia. et al. Cell Death & Disease. 2021.

 

Comprehensive identification of signaling pathways for idiopathic pulmonary arterial hypertension[J]. Bingxun Liu. et al. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY. 2020.

 

FOR RESEARCH USE ONLY